1. Startpage
  2. Johannes Gutenberg-Universität Mainz
  3. DFG-491381577-H
Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8604
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHess, Georg-
dc.contributor.authorHüttmann, Andreas-
dc.contributor.authorWitzens-Harig, Mathias-
dc.contributor.authorDreyling, Martin H.-
dc.contributor.authorKeller, Ulrich-
dc.contributor.authorMarks, Reinhard-
dc.contributor.authorErnst, Thomas-
dc.contributor.authorPott, Christiane-
dc.contributor.authorViardot, Andreas-
dc.contributor.authorFrontzek, Fabian-
dc.contributor.authorTrautmann, Marcel-
dc.contributor.authorRuckes, Christian-
dc.contributor.authorDeuster, Oliver-
dc.contributor.authorRosenwald, Andreas-
dc.contributor.authorTheobald, Matthias-
dc.contributor.authorLenz, Goerg-
dc.date.accessioned2023-01-19T10:14:00Z-
dc.date.available2023-01-19T10:14:00Z-
dc.date.issued2022-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8620-
dc.description.abstractThe prognosis of patients with relapsed diffuse large B-cell lymphoma (DLBCL) remains poor with current options. Here we prospectively evaluated the combination of pixantrone with obinutuzumab for up to six cycles for patients with relapsed or refractory DLBCL. Overall response rate (ORR) was the primary end-point. Sixty-eight patients were evaluated, median age was 75 years, median number of prior lines was three (range 1–10), 52 patients (76.5%) were diagnosed with DLBCL and 16 (23.5%) patients had transformed indolent lymphoma or follicular lymphoma (FL) IIIB. ORR was 35.3% for all and 40% for evaluable patients (16.6% complete response), median progression-free survival (PFS) and overall survival (OS) were 2.8 months and 8 months, respectively. Analysis of the cell of origin revealed a superior course for patients with non-GCB (germinal centre B-cell-like) phenotype [median OS not reached (n.r.) vs 5.2 months]. Patients with one prior line had an improved outcome over patients treated in later lines (PFS n.r. vs 2.5 months). Disease progression was the main reason for premature termination. Adverse events were mainly haematologic. The combination treatment revealed no unexpected adverse events. Most relevant non-haematologic toxicity was infection in 28% of patients. In summary, pixantrone–obinutuzumab showed clinical activity with sometimes long-term remission; however, the trial failed to meet its primary end-point.en_GB
dc.description.sponsorshipGefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577de
dc.language.isoengde
dc.rightsCC BY-NC-ND*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleA phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma : final results of the prospective, multicentre GOAL trialen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-8604-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleEuropean journal of heart failurede
jgu.journal.volume198de
jgu.journal.issue3de
jgu.pages.start482de
jgu.pages.end491de
jgu.publisher.year2022-
jgu.publisher.nameWileyde
jgu.publisher.placeOxfordde
jgu.publisher.issn1365-2141de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1111/bjh.18161de
jgu.organisation.rorhttps://ror.org/023b0x485-
jgu.subject.dfgLebenswissenschaftende
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
Thumbnail
a_phase_ii_trial_to_evaluate_-20230119110130294.pdf1.11 MBAdobe PDFView/Open
Show simple item record